Pancreatic Cancer Research

ResearcherThe University of Texas Health Science Center at HoustonActive in the last 2 years

Putao Cen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5633-311X; OpenAlex author ID A5004135808. Sources: ClinicalTrials.gov.

Their work

Papers
8
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 trial · 2026: 1 paper

Papers 8

  1. Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer Co-author DOI 10.64898/2026.04.05.713683↗
  2. EUS-guided radiofrequency ablation for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2024.04.2926↗
  3. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-22-0379↗
  4. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  5. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Co-author DOI 10.2174/1566524011313040001↗
  6. Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer. Co-author DOI 10.2174/1566524011313030009↗
  7. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2012.05.007↗
  8. Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. Co-author DOI 10.1111/j.1582-4934.2011.01478.x↗

Trials 1

  1. Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma Principal investigator NCT06831136↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Curtis Jackson Wray · 3 shared papers, 2023–2026 · strength 0.61
  2. Nirav C Thosani · 3 shared papers, 2023–2026 · strength 0.61
  3. Jennifer M. Bailey · 3 shared papers, 2023–2026 · strength 0.61
  4. Lincoln N. Strickland · 2 shared papers, 2023–2026 · strength 0.39
  5. Erika Yanil Faraoni · 2 shared papers, 2023–2024 · strength 0.37
  6. Urvinder Kaur Sardarni · 1 shared paper, 2026 · strength 0.23
  7. Khadija Shahab Turabi · 1 shared paper, 2026 · strength 0.23
  8. Jesse L. Cox · 1 shared paper, 2026 · strength 0.23
  9. MacKenzie V. Demmel · 1 shared paper, 2026 · strength 0.23
  10. Sunil R. Hingorani · 1 shared paper, 2026 · strength 0.23
  11. Jingxuan Yang · 5 shared papers, 2012–2015 · strength 0.18
  12. Xianjun Yu · 3 shared papers, 2013–2015 · strength 0.10
  13. Xiaoling Ni · 2 shared papers, 2012 · strength 0.08
  14. Min Li · 2 shared papers, 2012–2015 · strength 0.08
  15. Jiang Long · 2 shared papers, 2012–2015 · strength 0.08
  16. Xiaobo Cui · 2 shared papers, 2013 · strength 0.06
  17. Min Li · 1 shared paper, 2012 · strength 0.04
  18. Quanxing Ni · 1 shared paper, 2015 · strength 0.04
  19. Aminah Jatoi · 1 shared paper, 2015 · strength 0.04
  20. Angela L. McCleary‐Wheeler · 1 shared paper, 2015 · strength 0.04
  21. Jin Xu · 1 shared paper, 2015 · strength 0.04
  22. Huaxiang Xu · 1 shared paper, 2015 · strength 0.04
  23. Wenquan Wang · 1 shared paper, 2015 · strength 0.04
  24. Liang Liu · 1 shared paper, 2015 · strength 0.04
  25. Yong Chen · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.